Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants

Journal of Pharmaceutical Sciences

Volumn 96, Issue 9, 2007, Pages 2375-2389

  Vessely, Christina ^a   Estey, Tia ^a   Randolph, Theodore W ^b   Henderson, Ian ^c   Nayar, Rajiv ^d   Carpenter, John F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UCB 450   (United States)

^c A CSC Company   (United States)

^d HTD Biosystems   (United States)

Author keywords

Aluminum salt adjuvant; Botulinum neurotoxin; Competitive adsorption; Recombinant vaccine

Indexed keywords

ADJUVANT; ALUMINUM SALT; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; PHOSPHATE; RECOMBINANT ANTIGEN; TRIPLE VACCINE;

ADSORPTION KINETICS; ARTICLE; CHEMISTRY; DRUG ADSORPTION; DRUG DEVELOPMENT; DRUG POTENCY; ELECTRICITY; EVALUATION; MASS SPECTROMETRY; PROTEIN CONTENT; SOLUTION AND SOLUBILITY; SURFACE PROPERTY;

EID: 34748895084     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20880     Document Type: Article

References (51)

1. Ting P, Freiman A. 2004. The story of Clostridium botulinum: From food poisoning to botox. Clin Med 4:258-261.
2. Erbguth F. 2004. Historical notes on botulism, clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Move Disord 19:S2-S6.
3. Erbguth F, Naumann M. 1999. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology 53:1850-1853.
4. Yang G, Kim K, Jeong S, Huh G, Kim J, Jungh H. 2004. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B. Toxicon 44:19-25.
5. Cherington M. 1998. Clinical spectrum of botulism. Mus Nerve 21:701-710.
6. Arnon S, Schechter R, Inglesby T, Henderson D, Bartlett J, Ascher M, Eitzen E, Fine A, Hauer J, Layton M, Lillibridge S, Osterholm M, O'toole T, Parker G, Perl T, Russell P, Swerdlow D, Tonat T. 2001. Botulinum toxin as a biological weapon - medical and public health management. J Am Med Ass 285:1059-1070.
7. Comelia C, Pullman S. 2004. Botulinum toxins in neurological disease. Mus Nerve 29:628-644.
8. Middlebrook J, Franz D. 1997. Medical aspects of chemical and biological warfare: Botulinum toxins. In: Sidell F, Takafuji E, Franz D, editors. Warfare, weaponry, and the casualty, Washington, DC: TMM Publications: pp 643-654.
9. Turton K, Chaddock J, Acharya K. 2002. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem Sci 27:552-558.
10. DePaz RA, Henderson I, Advant S. 2005. Formulation of botulinum neurotoxin heavy chain fragments for vaccine development: Mechanisms of adsorption to an aluminum-containing adjuvant. Vaccine 23:4029-4035.
11. Byrne M, Smith L. 2000. Development of vaccines for prevention of botulism. Biochimie 82:955-966.
12. Mclnerny T, Brennan F, Jones T, Dimmock N. 1999. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine 17:1359-1368.
13. Singh M, O'Hagan D. 1999. Advances in vaccine adjuvants. Nat Biotechnol 17:1075-1081.
14. O'Hagan D, MacKichan M, Singh M. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18:69-85.
15. Rinella J, Workman R, Hermodson M, White J, Hem S. 1998. Elutability of proteins from aluminum-containing vaccine adjuvants by treatment with surfactants. J Colloid Interface Sci 197:48-56.
16. Jendrick S, Little S, Hem S, Mitra G, DGiardina S. 2003. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine 21:3011-3018.
17. Lindblad E. 2004. Aluminum adjuvants - In retrospect and prospect. Vaccine 22:3658-3668.
18. Petrovsky N, Aguilar J. 2004. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 85:488-496.
19. Eldridge J, Staas J, Mueulbroek A, Tice T, Gilley R. 1991. Biodegradable and biocompatible poly(DL-Lactide-Co-Glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59:2978-2986.
20. Glenny A, Buttle G, Stevens M. 1931. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: Toxoid precipitated with alum. J Pathol Bacteriol 34:267-275.
21. Gupta R, Rost B, Releveld E, Siber G. 1995. Adjuvant properties of aluminum and calcium compounds. In: Powell M, Newman M, editors. Pharmaceutical biotechnology, New York: Plenum Press: pp 229-248.
22. Holt L. 1950. Developments in diphtheria prophylaxis, London: Heinemann Medical Books. pp 1-181.
23. White R, Coons A, Connolly J. 1955. Studies on antibody production: III. The alum granuloma. J Exp Med 102:73-82.
24. Mannhalter J, Neychev H, Zalabinger G, Ahmad R, Eibl M. 1985. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminum hydroxide: Effect of antigen uptake and antigen presentation. Clinic Exp Immunol 61:143-151.
25. Rimaniol A, Gras G, Verdier F, Capel F, Grigoriev V, Porcheray F, Sauzeat E, Fournier J, Clayette P, Siegrist C, Dormont D. 2004. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22:3127-3135.
26. Flebbe L, Braley-Mullen H. 1986. Immunopotentiating effects of adjuvants SGP and Quil A. Cell Immunol 99:119-127.
27. Ramanathan V, Badenoch-Jones P, Turk J. 1979. Complement activation by aluminum and zirconium compounds. Immunology 37:881-888.
28. White J, Hem S. 2000. Characterization of aluminum-containing adjuvants. In: Brown F, Corbel M, Griffiths E, editors. Physico-chemical procedures for the characterization of vaccines, Basel: Karger: pp 217-228.
29. Jones K, O'Melia C. 2000. Protein and humic acid adsorption onto hydrophilic membrane surfaces: Effects of pH and ionic strength. J Membrane Sci 165:31-46.
30. Iyer S, Robinett R, HogenEsch H, Hem S. 2004. Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine 22:1475-1479.
31. Jones L, Peek L, Power J, Markham A, Yazzie B, Middaugh C. 2005. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model proteins. J Biol Chem 280:13406-13414.
32. Everett D. 1964. Thermodynamics of adsorption from solution. Part I. Perfect systems. Trans Faraday Soc 60:1803-1813.
33. Ruthven D. 1984. Principles of adsorption and desorption processes, New York: Wiley.
34. Blom N, Gammeltoft S, Brunak S. 1999. Sequence-and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 294:1351-1362.
35. Norde W, Zoungrana T. 1998. Surface-induced changes in the structure and activity of enzymes physically immobilized at solid/liquid interfaces. Biotechnol Appl Biochem 28:133-143.
36. Shi Y, HogenEsch H, Hem S. 2002. Change in the degree of adsorption of proteins by aluminium - containing adjuvants following exposure to interstitial fluid: Freshly prepared and aged model vaccines. Vaccine 20:80-85.
37. Callahan P, Shorter A, Hem S. 1991. The importance of surface charge in the optimization of antigen-adjuvant interactions. Pharm Res 8:851-857.
38. Gupta R. 1998. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32:155-172.
39. Hem S, White J. 1995. Structure and properties of aluminum-containing adjuvants. In: Powell M, Newman M, editors. Vaccine design: The subunit and adjuvant approach, New York: Plenum Press, pp 249-276.
40. Alshakhshir R, Regnier F, White J, Hem S. 1995. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminum-containing adjuvants. Vaccine 13:41-44.
41. Rinella J, White J, Hem S. 1995. Effect of anions on model aluminum-adjuvant-containing vaccines. J Colloid Interface Sci 172:121-130.
42. Liu J, Feldkamp J, White J, Hem S. 1984. Adsorption of phosphate by aluminum hydroxycarbonate. J Pharm Sci 73:1355-1358.
43. Sema C, White J, Hem S. 1977. Anion-aluminum hydroxide gel interactions. Soil Sci Soc Am J 41:1009-1013.
44. Rinella J, Workman R, Hermodson M, White J, Hem S. 1998. Elutability of proteins from aluminum-containing vaccine adjuvants by treatment with surfactant. J Colloid Interface Sci 197:48-56.
45. Iyer S, HogenEsch H, Hem S. 2003. Effect of the degree of phosphate substitution in aluminum hydroxide adjuvant on the adsorption of phosphorylated proteins. Pharm Develop Technol 8:81-86.
46. Hingston F, Atkinson R, Quirk J. 1967. Specific adsorption of anions. Nature (London) 215:1459-1461.
47. Vogel F, Powell M. 1995. A summary compendium of vaccine adjuvants and excipients. In: Powell M, Newman M, editors. Vacine design: The subunit and adjuvant approach, New York: Plenum Publishing Corporation.
48. Christoph G, Corbato C, Hofmann D, Tettenhorst R. 1979. Crystal structure of boehmite. Clays Clay Min 27:81-86.
49. Chang M-F, White J, Nail S, Hem S. 1997. Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant. PDA J Pharm Sci Technol 51:25-29.
50. Seeber S, White J, Hem S. 1991. Predicting adsorption of proteins by aluminum containing adjuvants. Vaccine 9:201-203.
51. Norde W, Lyklema J. 1991. Why proteins prefer interfaces. J Biomater Sci Polym Ed 2:183-202.